- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06938412
Intervención de actividad de ejercicio con participación basada en sensores en pacientes con fibrilación auricular (EASE-AF)
Intervención de actividad de ejercicio con participación basada en sensores en pacientes con fibrilación auricular (facilidad-AF)
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, non-permanent AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jaclyn Printz
- Número de teléfono: 917-991-674
- Correo electrónico: EASE-AF@mountsinai.org
Copia de seguridad de contactos de estudio
- Nombre: Jaclyn Printz
- Número de teléfono: 212-824-7077
- Correo electrónico: Jaclyn.Printz@mountsinai.org
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Icahn School of Medicine at Mount Sinai
-
Investigador principal:
- Janice Y Chyou, MD
-
Contacto:
- Jaclyn Printz
- Correo electrónico: EASE-AF@mountsinai.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- ≥40years of age
- non-permanent AF
- Electrocardiographic (or equivalent) documentation of AF within 36 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
- AF Severity Scale (AFSS) symptom score 6-26
- Self-report weekly moderate-vigorous physical activity (MVPA) < 150 minutes
Exclusion Criteria:
- Unable to give consent
- ≤90 days from AF ablation, coronary revascularization, heart failure hospitalization
- Left ventricular ejection fraction (LVEF) <40%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
- Labile INR or unable to take anticoagulant despite indication
- Life expectancy < 1 year
- Hemodialysis; severe pulmonary or liver disease
- Musculoskeletal, balance/gait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise
- Upon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of <150 minutes), the participant will be further excluded.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Patients With Atrial Fibrillation
Patients with symptomatic, non-permanent AF. |
The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS), Symptom Severity Domain
Periodo de tiempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The Symptom Severity domain (Part C) of the validated Atrial Fibrillation Severity Scale (AFSS) questions patients regarding the severity of 7 AF-related symptoms (on scale of 0-5 per question, 5 denoting a great deal of symptom and 0 with no symptom) over the preceding 4-week period. Total scores range 0-35 on the Symptom Severity Domain of the Atrial Fibrillation Severity Scale (AFSS), higher score denotes more severe AF-related symptoms. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS)
Periodo de tiempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The full Atrial Fibrillation Severity Scale (AFSS) is composed of 19-items, investigating four domains: global well-being, symptom burden, health care utilization, symptom severity. Global well-being: 1-10; 10 denotes best possible quality of life. Symptom burden: Composite of AF burden as AF duration + AF frequency + AF severity; ranging 0-30, higher denotes more symptom burden. Health care utilization: ER visits (0-7, higher number denotes more utilization), Hospitalizations (0-7, higher number denotes more utilization), Specialist visits (0-7, higher number denotes more utilization); Symptom Severity: 0-35, higher score denotes more severe AF-related symptoms |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Percentage of time in AF
Periodo de tiempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Global AF arrhythmia burden will be measured as percentage of time in AF measured during an 8-14-day monitoring period at the end of each time point as quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Duration of longest AF Arrhythmia Episode
Periodo de tiempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Duration of the longest AF episode during the monitoring period will be quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Step Counts
Periodo de tiempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly step counts measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Exercise Minutes
Periodo de tiempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly exercise minutes measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Janice Y Chyou, MD, Icahn School of Medicine at Mount Sinai
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY-24-00464
- 24SCEFIA1249819 (Otro número de subvención/financiamiento: American Heart Association)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Not planning to share individual participant data. Aggregate data will be shared instead.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .